Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Search Results

411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of brain (B-type) natriuretic peptide on coronary artery diameter and coronary hemodynamic variables in humans: comparison with effects on systemic hemodynamic variables.
Okumura K, Yasue H, Fujii H, Kugiyama K, Matsuyama K, Yoshimura M, Jougasaki M, Kikuta K, Kato H, Tanaka H, et al. Okumura K, et al. Among authors: kikuta k. J Am Coll Cardiol. 1995 Feb;25(2):342-8. doi: 10.1016/0735-1097(94)00407-h. J Am Coll Cardiol. 1995. PMID: 7829786 Free article.
Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial.
Sakamoto T, Ogawa H, Nakao K, Hokimoto S, Tsujita K, Koide S, Yamamoto N, Shimomura H, Matsumura T, Oshima S, Kikuta K, Oka H, Kimura K, Matsui K; 4C (Candesartan for Prevention of Cardiovascular Events after CYPHER™ or TAXUS™ Coronary Stenting) study investigators. Sakamoto T, et al. Among authors: kikuta k. J Cardiol. 2016 Apr;67(4):371-7. doi: 10.1016/j.jjcc.2015.06.009. Epub 2015 Aug 4. J Cardiol. 2016. PMID: 26254019 Free article. Clinical Trial.
Rationale, design and baseline characteristics of a study to evaluate effects of candesartan on cardiovascular events after drug-eluting stent implantation in patients with ischemic heart disease.
Sakamoto T, Ogawa H, Nakao K, Koide S, Yamamoto N, Shimomura H, Matsumura T, Oshima S, Kikuta K, Oka H, Kimura K, Matsui K; 4C (Canderstan for Prevention of Cardiovascular Events after CYPHER or TAXUS Coronary Stenting) investigators. Sakamoto T, et al. Among authors: kikuta k. J Atheroscler Thromb. 2013;20(5):472-80. doi: 10.5551/jat.13870. Epub 2013 Mar 14. J Atheroscler Thromb. 2013. PMID: 23411616 Free article. Clinical Trial.
Dose-Dependent Inhibitory Effect of Rosuvastatin in Japanese Patients with Acute Myocardial Infarction on Serum Concentration of Matrix Metalloproteinases-INVITATION Trial.
Shirakawa T, Fujisue K, Nakamura S, Yamamoto N, Oshima S, Matsumura T, Tsunoda R, Hirai N, Koide S, Tayama S, Kikuta K, Hirose T, Maruyama H, Fujimoto K, Kajiwara I, Sakamoto T, Nakao K, Sakaino N, Nagayoshi Y, Hokamaki J, Shimomura H, Sakamoto K, Yamamoto E, Izumiya Y, Kaikita K, Hokimoto S, Ogawa H, Tsujita K. Shirakawa T, et al. Among authors: kikuta k. J Atheroscler Thromb. 2022 Feb 1;29(2):229-241. doi: 10.5551/jat.59477. Epub 2021 Jan 7. J Atheroscler Thromb. 2022. PMID: 33408315 Free PMC article. Clinical Trial.
Impact of cerebrovascular comorbidity on prognosis in Japanese patients undergoing PCI: 1-year data from Japanese multicenter registry (KICS).
Ahmed K, Arima Y, Tabata N, Ishii M, Sato R, Yamashita T, Yamanaga K, Takizawa H, Hokimoto S, Sueta D, Araki S, Fujisue K, Takashio S, Fujimoto K, Shimomura H, Tsunoda R, Hirose T, Sato K, Kikuta K, Sakaino N, Nakamura S, Yamamoto N, Matsumura T, Kajiwara I, Tayama S, Sakamoto T, Nakao K, Oshima S, Yamamoto E, Sakamoto K, Kaikita K, Matsushita K, Tsujita K. Ahmed K, et al. Among authors: kikuta k. Heart Vessels. 2022 Jun;37(6):911-918. doi: 10.1007/s00380-021-01997-7. Epub 2022 Jan 11. Heart Vessels. 2022. PMID: 35013771
411 results